During the three-day summit, Cooper will host a series of one-on-one sessions with institutional investors and prospective industry partners. These discussions aim to highlight the company’s recent operational progress and upcoming milestones for its proprietary Bisphosphocin platform. The firm focuses on addressing antibiotic-resistant bacterial threats, including MRSA and VRE, through its fast-acting therapeutic candidates. The presentation serves as a key touchpoint for the Sarasota-based company as it advances its clinical pipeline.
In section Releases
Lakewood-Amedex CEO Heads to H.C. Wainwright Global Investment Summit
CEO Kelvin Cooper is set to represent Lakewood-Amedex Biotherapeutics at the H.C. Wainwright 28th Annual Global Investment Conference in New York. Running from September 14 to 16, 2026, the event provides a platform for the clinical-stage firm to outline its development strategy for a novel class of broad-spectrum antimicrobials.
Comments (0)
No comments yet. Be the first!